Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene

被引:7
|
作者
Shulskaya, Marina V. [1 ]
Shadrina, Maria I. [1 ]
Fedotova, Ekaterina Yu. [2 ]
Abramycheva, Nataliya Yu. [2 ]
Limborska, Svetlana A. [1 ]
Illarioshkin, Sergey N. [2 ]
Slominsky, Petr A. [1 ]
机构
[1] Russian Acad Sci, Inst Mol Genet, Dept Mol Basics Human Genet, Moscow, Russia
[2] Fed State Sci Inst, Dept Neurogenet, Sci Ctr Neurol, Moscow, Russia
基金
俄罗斯科学基金会; 俄罗斯基础研究基金会;
关键词
Parkinson's disease; PARK2; point mutations; exon rearrangements; EARLY-ONSET PARKINSONISM; COPY NUMBER VARIATIONS; CARRIERS; DOSAGE; PINK1; SUSCEPTIBILITY; VARIANTS; COHORT; COMMON; LRRK2;
D O I
10.1080/00207454.2016.1255612
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aim of the study: Mutations in PARK2 are one of the causes of Parkinson's disease (PD). Deletions and duplications/triplications of one exon or exon groups account for a large proportion of mutations in the gene. At the present time, it is still not fully clear whether heterozygous mutations cause the development of PD. Our study aimed at conducting screening for mutations in PARK2 in patients with a sporadic form of PD to clarify the role of PARK2 in the development of PD. Materials and methods: The cohort of 327 patients with PD was screened by quantitative real-time polimerase chain reaction (PCR) with subsequent Sanger sequencing. Results: It was found that a sufficiently large proportion of these patients (21 patients, 6.4%) were carriers of heterozygous deletions or duplications in PARK2. Analysis of PARK2 exon rearrangement carriers for the presence of point mutations in PARK2 did not reveal any variants with pathogenic significance. Conclusions: Thus, our data indicate that heterozygous deletions and duplications can play an important role in the pathogenesis of PD and can be considered as dominant mutations with low penetrance.
引用
收藏
页码:781 / 784
页数:4
相关论文
共 50 条
  • [1] Analysis of PARK2 Gene Exon Rearrangements in Russian Patients with Sporadic Parkinson's Disease
    Semenova, Elena V.
    Shadrina, Maria I.
    Slominsky, Pyotr A.
    Ivanova-Smolenskaya, Irina A.
    Bagyeva, Gulbakhar
    Illarioshkin, Sergei N.
    Limborska, Svetlana A.
    MOVEMENT DISORDERS, 2012, 27 (01) : 139 - 142
  • [2] PARK2 gene variants in Korean patients with Parkinson's disease
    Park, Min-young
    Park, In won
    Ihm, Chun Hwa
    Kim, Eunhee
    GENES & GENOMICS, 2016, 38 (02) : 163 - 169
  • [3] Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease
    Kobayashi, T
    Wang, M
    Hattori, N
    Matsumine, H
    Kondo, T
    Mizuno, Y
    PARKINSONISM & RELATED DISORDERS, 2000, 6 (03) : 129 - 131
  • [4] PARK2 gene variants in Korean patients with Parkinson’s disease
    Min-young Park
    In won Park
    Chun hwa Ihm
    Eunhee Kim
    Genes & Genomics, 2016, 38 : 163 - 169
  • [5] Identification of mutations in the PARK2 gene in Serbian patients with Parkinson's disease
    Jankovic, M. Z.
    Dobricic, V.
    Kresojevic, N.
    Markovic, V.
    Petrovic, I.
    Svetel, M.
    Pekmezovic, T.
    Novakovic, I.
    Kostic, V.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 393 : 27 - 30
  • [6] Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's Disease
    Chu, Min Kyung
    Kim, Won Chan
    Choi, Jung Mi
    Hong, Jeong-Hoon
    Kang, Suk Yun
    Ma, Hyeo-Il
    Kim, Yun Joong
    JOURNAL OF CLINICAL NEUROLOGY, 2014, 10 (03): : 244 - 248
  • [7] Novel compound heterozygous mutations in the PARK2 gene identified in a Chinese pedigree with early-onset Parkinson's disease
    Shi, Yingying
    Kawakami, Hideshi
    Zang, Weizhou
    Li, Gang
    Zhang, Jiewen
    Xu, Changshui
    BRAIN AND BEHAVIOR, 2018, 8 (01):
  • [8] Point Mutation in the Parkin Gene on Patients with Parkinson's Disease
    王涛
    梁直厚
    孙圣刚
    曹学兵
    彭海
    曹非
    刘红进
    童萼塘
    Current Medical Science, 2003, (02) : 145 - 147
  • [9] Point mutation in the parkin gene on patients with Parkinson’s disease
    Wang Tao
    Liang Zhihou
    Sun Shenggang
    Cao Xuebing
    Peng Hai
    Cao Fei
    Liu Hongjin
    Tong E-tang
    Current Medical Science, 2003, 23 (2) : 145 - 147
  • [10] Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson's disease
    Huttenlocher, Johanna
    Stefansson, Hreinn
    Steinberg, Stacy
    Helgadottir, Hafdis T.
    Sveinbjornsdottir, Sigurlaug
    Riess, Olaf
    Bauer, Peter
    Stefansson, Kari
    HUMAN MOLECULAR GENETICS, 2015, 24 (19) : 5637 - 5643